Sagimet Biosciences (SGMT) Other Non Operating Income (2022 - 2026)
Sagimet Biosciences (SGMT) posted quarterly Other Non Operating Income of $1.1 million for Q1 2026, down 37.06% year-over-year from $1.7 million in Q1 2025, and down 11.19% quarter-over-quarter from $1.2 million in Q4 2025.
Sagimet Biosciences (SGMT) Other Non Operating Income (2022 - 2026) Analysis & Trends
Sagimet Biosciences' Other Non Operating Income history runs 5 years deep, the most recent figure standing at $1.1 million for Q1 2026.
- In Q1 2026, Other Non Operating Income fell 37.06% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $5.2 million (down 38.07% YoY), while the FY2025 annual figure was $5.9 million, down 34.16% from the prior year.
- Other Non Operating Income for Q1 2026 stood at $1.1 million, down from $1.2 million in the prior quarter.
- The five-year high for Other Non Operating Income was $2.5 million in Q2 2024, with the low at $136000.0 in Q2 2022.
- The 5-year median for Other Non Operating Income is $1.3 million (2023), against an average of $1.2 million.
- The sharpest annual moves came in 2024 and 2025: Other Non Operating Income jumped 1101.69% in 2024, then tumbled 39.97% in 2025.
- Sagimet Biosciences' Other Non Operating Income stood at $193000.0 in 2022, then surged by 581.35% to $1.3 million in 2023, then jumped by 51.63% to $2.0 million in 2024, then plunged by 39.97% to $1.2 million in 2025, then fell by 11.19% to $1.1 million in 2026.
- Business Quant data shows SGMT's Other Non Operating Income at $1.1 million in Q1 2026, $1.2 million in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Sagimet Biosciences | 649.79 Mn | 649.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.87 Mn |
| Mar 31, 2026 | 1.06 Mn |
| Dec 31, 2025 | 1.20 Mn |
| Sep 30, 2025 | 1.43 Mn |
| Jun 30, 2025 | 1.54 Mn |
| Mar 31, 2025 | 1.69 Mn |
| Dec 31, 2024 | 1.99 Mn |
| Sep 30, 2024 | 2.28 Mn |
| Jun 30, 2024 | 2.47 Mn |
| Mar 31, 2024 | 2.14 Mn |
| Dec 31, 2023 | 1.32 Mn |
| Sep 30, 2023 | 1.10 Mn |
| Jun 30, 2023 | 272,000.00 |
| Mar 31, 2023 | 178,000.00 |
| Dec 31, 2022 | 193,000.00 |
| Sep 30, 2022 | 219,000.00 |
| Jun 30, 2022 | 136,000.00 |